受体酪氨酸激酶EphB6在卵巢浆液性癌中的表达及其意义

目的 探讨受体酪氨酸激酶EphB6在卵巢浆液性癌中的表达及其与临床病理特征的关系。方法 采用免疫组织化学染色检测EphB6蛋白在55例卵巢浆液性癌、24例卵巢良性肿瘤、37例卵巢交界性肿瘤和20例正常输卵管组织蜡块中的表达情况，并分析EphB6蛋白表达与卵巢癌临床病理特征及预后之间的相关性。结果 EphB6蛋白在100.0％（20／20）正常输卵管、100.0％（24／24）卵巢良性肿瘤、78.4％（29／37）卵巢交界性肿瘤和18.2％（10／55）卵巢浆液性癌组织中高表达（P＜0.001）。EphB6蛋白表达水平与肿瘤分化程度、TNM分期及Ki 67表达均有关（P＜0.05）。EphB6高表达组和EphB6中、低表达组的中位生存期（OS）分别为103个月和69个月（95％CI：26～105个月），差异有统计学意义（P=0.046）。结论 EphB6将有可能成为一种新的鉴别卵巢肿瘤高、低级别的标志物和预测预后的新指标。

Expression of EphB6 receptor tyrosine kinase in ovarian serous carcinoma and its clinical significance

Objective To investigate the expression of receptor tyrosine kinase EphB6 in ovarian serous carcinoma and its re-lationship with clinicopathological characteristics. Methods Immunohistochemical staining was subjected to a set of paraffin fixed tis-sue samples including 55 cases of ovarian serous carcinoma, 24 cases of benign carcinoma, 37 cases of borderline carcinoma and 20 cases of normal fallopian tube. The relationship between the expression of EphB6 in ovarian serous carcinoma and clinicopathological parameters and survival was analyzed. Results High expression of EphB6 was detected in 100. 0%( 20/20) of normal fallopian tube samples, 100. 0%(24/24) of benign carcinoma, 78. 4%(29/37) of borderline tumor and 18. 2%(10/55) of ovarian serous carcinoma ( P<0. 001) . The expression of EphB6 was significantly associated with differentiation, TNM stage and Ki-67( P<0. 005) . The median overall survival of high-level expression group was 103 months, higher than 69( 95%CI:26-105) months of moderate and low-level ex-pression group with significant difference(P=0. 046). Conclusion It shows that EphB6 is a new biomarker for distinguishing high and low-grade ovarian serous carcinoma, and maybe a potential prognostic marker.